Superworth

Yarrow Bioscience EPS YARW

Diluted earnings per share by quarter and over the last twelve months, from 2016.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$3.51
Fiscal year 2024
−$47.00

Yarrow Bioscience's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$3.51.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2024−$47.00n/a
FY2022−$357.00n/a
FY2021−$1296.00n/a
FY2020−$1962.00n/a
FY2019$0.00n/a
FY2018−$8640.00n/a
FY2017−$20484.00n/a
FY2016−$10044.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$3.51n/an/a
Q1 FY26−$4.00n/an/a
Q2 FY25−$6.73n/a−$45.23
Q1 FY25−$10.00n/a−$49.50
Q4 FY24−$14.00n/a−$47.00
Q3 FY24−$14.50n/an/a
Q2 FY24−$11.00n/an/a
Q1 FY24−$7.50n/an/a
Q3 FY23−$100.50n/a−$496.00
Q2 FY23−$154.50n/a−$542.50
Q1 FY23−$87.00−215%−$519.50
Q4 FY22−$154.00n/a−$357.00

Against its peers

Companies in Drug Manufacturers - General nearest Yarrow Bioscience's size, closest first, today.

CompanyEPS, 12 monthsGrowth
YARWYarrow Biosciencen/m
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Yarrow Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.